Mr. Hugh Rogers reports

BIONXT SOLUTIONS ANNOUNCES INVESTOR RELATIONS AGREEMENTS AND OPTION GRANTS

Bionxt Solutions Inc. has entered into agreements with certain investment relations service providers and granted an aggregate of 5.15 million stock options to insiders, employees, consultants and investor relations service providers of the company, pursuant to the company's stock option plan.

On Feb. 27, 2026, the company entered into an agreement with Clay McMeekin of Victoria, B.C., pursuant to which Mr. McMeekin will provide to the company certain investor relations services, including, but not limited to, targeting institutional investors (pension funds, hedge funds and family offices) and qualified retail (individual) investors. Under the terms of the agreement, Mr. McMeekin will provide the services from Feb. 27, 2026, until Aug. 31, 2026. In consideration of the services, the company will grant Mr. McMeekin one million options, each entitling Mr. McMeekin to acquire one common share at an exercise price of 63 cents per common share for a period of two years, in accordance with the option plan. Twenty-five per cent of the options granted to Mr. McMeekin will vest every three months following the date of grant until the date that is 12 months following the date of grant.

On Feb. 27, 2026, the company also formalized the renewal of its agreement dated Aug. 22, 2025, with Cayo Ventures GmbH, wholly owned by Yves Toelderer of Zug, Switzerland, pursuant to which Cayo will provide to the company certain investor relations services, including, but not limited to, German language video interviews, opt-in e-mail news distribution and digital marketing services. Services will be provided in Europe until June 30, 2026, with services and compensation up to a total of 30,000 euros per week depending on success as measured by observed trading activity in Europe. Additionally, the company granted to Yves Toelderer, principal of Cayo, 250,000 options, each entitling Mr. Toelderer to acquire one common share at an exercise price of 63 cents per common share for a period of two years, in accordance with the option plan. Twenty-five per cent of the options granted to Mr. Toelderer will vest every three months following the date of grant until the date 12 months following the date of grant.

Additionally, the company granted 3.8 million options, each entitling the holder thereof to acquire one common share in the capital of the company at an exercise price of 63 cents per common share for a period of five years, to certain insiders, consultants and an employee of the company, and all such options vested immediately. The company also granted 100,000 options, each entitling the holder thereof to acquire one common share at an exercise price of 63 cents per common share for a period of two years, to certain consultants of the company. All such options vested immediately.

The option plan was last approved by the shareholders of the company on Nov. 7, 2025.

The options and any underlying common shares in the capital of the company will be subject to a four-month-and-one-day hold period pursuant to the policies of the Canadian Securities Exchange.

About Bionxt Solutions Inc.

Bionxt is a bioscience innovator focused on next-generation drug delivery platforms, diagnostic screening systems and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets and a new targeted chemotherapy platform designed to deliver cancer drugs directly to tumours while reducing side effects.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange and OTC Markets, and trades in Germany under WKN: A3D1K3.